Idiopathic intracranial hypertension (IIH) is a condition of elevated intracranial pressure without an identifiable secondary cause. First-line management combines a lifestyle intervention with pharmacologic therapy, each aimed at reducing intracranial pressure and reversing disease-related changes.
First-line care for IIH pairs weight loss with a primary pharmacologic agent; alternatives are available for patients who cannot tolerate the initial therapy. The complete regimen — including agent selection, sequencing, and escalation — is in the full protocol.
Treatment targets improvement of papilledema and reduction of intracranial pressure, with the aim of achieving resolution of IIH with an adequate response.